Herpes simplex virus (HSV) is a common virus that lives in the body for life. It belongs to a family of viruses that can lie dormant and reactivate from time to time, often without warning. There are two main types: HSV-1 and HSV-2. While both types share similarities, they differ in how they’re typically spread, where symptoms show up, and how often those symptoms return.
HSV-1 is usually picked up in childhood, often through close contact like kissing or sharing utensils. It’s best known for causing cold sores around the mouth, but it’s also becoming a more common cause of genital herpes, especially through oral-genital contact. On the other hand, HSV-2 is most often spread through sexual contact and is strongly linked to genital herpes. Many people with HSV-2 don’t know they have it, but it can cause painful outbreaks, especially the first time symptoms appear.
Understanding the difference between HSV-1 and HSV-2 can make a big impact on your health. It helps doctors give the right diagnosis, allows for better prevention strategies, and guides treatment decisions. For example, special blood tests can tell the two types apart and help figure out where the infection likely started. If someone has symptoms, tests like PCR can quickly spot the virus and confirm what’s going on.
Knowing your HSV type also helps reduce the risk of passing it to others. HSV-2, in particular, is linked to a higher chance of getting or spreading HIV. People who know their diagnosis tend to make more informed choices—like using protection or having open conversations with partners.
Finally, it’s important to clear up a few common myths. HSV-1 doesn’t just affect the mouth—it can cause genital herpes, too. In fact, in some areas, it’s responsible for a growing number of genital cases. And while HSV-2 almost always affects the genitals, it can occasionally show up in the mouth, though this is rare. Both viruses can be passed on even when no symptoms are showing, which is why understanding the differences matters.
HSV-1 Transmission
HSV-1, or herpes simplex virus type 1, is most often passed through oral contact—especially in childhood. It’s a very common virus, and many people carry it without ever knowing.
In most cases, HSV-1 is picked up early in life through everyday interactions like kissing, sharing drinks or utensils, or being cared for by someone who has the virus. The virus can spread even when no visible symptoms are present, which is part of what makes it so widespread. In children, a first-time infection might show up as a cold sore or a mild illness involving the mouth and gums.
Cultural and social conditions also shape how HSV-1 spreads. In many lower-income or developing regions, kids tend to acquire HSV-1 early. But in wealthier, more industrialized countries, the age of first exposure is shifting. Improved hygiene and fewer early-life exposures mean some people are reaching adulthood without ever having been infected—something that increases their chances of a genital HSV-1 infection later on.
That brings us to an important point: HSV-1 isn’t only oral. Over the past few decades, genital HSV-1 infections have been on the rise, especially in younger adults. This is mostly due to oral-genital contact. When someone with an oral HSV-1 infection performs oral sex, the virus can be passed to a partner’s genitals—even if they don’t have visible cold sores at the time.
This shift means that many people who never had HSV-1 as children are now encountering it during sexual activity. Women, in particular, may be more likely to get genital HSV-1 from partners who have oral HSV-1, especially if protection isn’t used during oral sex.
In very rare cases, HSV-1 can even spread from a person’s own mouth to their genitals through hand contact during an active outbreak—something called autoinoculation. While not common, it’s a reminder that the virus doesn’t always follow predictable paths.
Understanding how HSV-1 spreads helps clarify the difference between HSV-1 and HSV-2, especially when it comes to risk and prevention. While HSV-1 has long been associated with oral herpes, it’s playing a growing role in genital infections, too.
HSV-2 Transmission
HSV-2, or herpes simplex virus type 2, is primarily spread through sexual contact. Unlike HSV-1, which is often picked up in childhood, HSV-2 is almost always acquired during sexual activity, including vaginal, anal, and sometimes oral sex. It spreads through skin-to-skin contact, especially when the virus is active—even if there are no visible symptoms.
One of the most challenging aspects of HSV-2 transmission is that many people don’t know they have it. The virus can be passed on through asymptomatic shedding, which means it can spread even when there are no sores or obvious signs. This silent transmission is a big part of why HSV-2 is so common and why routine testing and open conversations are so important.
Women face a higher biological risk of acquiring HSV-2, largely due to the structure of the genital tract, which presents more mucosal surface area during sex. In relationships where one partner has HSV-2 and the other does not, women are statistically more likely to contract the virus. That doesn’t mean men aren’t at risk—but it does highlight the need for tailored prevention strategies.
While HSV-2 is usually passed between adults, it can also be transmitted during childbirth if a pregnant person has a new or active infection. This is rare but serious, as neonatal herpes can lead to severe complications in newborns. That’s why doctors often recommend antiviral treatment in late pregnancy for those with a known HSV-2 diagnosis.
Having multiple sexual partners or using condoms inconsistently also raises the risk of HSV-2 transmission. Studies show that people with more sexual partners—especially those who don’t use protection regularly—are more likely to get the virus. On the other hand, even partial condom use can offer significant protection. One study found that using condoms in just a quarter of sexual encounters lowered a woman’s risk of HSV-2 by more than 80%.
Certain groups, such as sex workers or individuals in non-monogamous relationships, often have higher rates of HSV-2, not because of personal choices alone, but due to structural factors like access to health care, education, and protection. In these populations, condom use is key, but so is reducing stigma and making it easier for people to get tested, treated, and supported.
Understanding how HSV-2 spreads is essential in grasping the difference between HSV-1 and HSV-2, especially when it comes to prevention and education. HSV-2 may carry a heavier burden in terms of transmission risk, but with knowledge and the right tools, it can be managed and shared responsibly in relationships.
Symptom Presentation: How They Differ
While herpes simplex virus types 1 and 2 share some similarities, their symptoms often show up in different parts of the body and follow different patterns—especially when it comes to how often they recur and how severe they feel.
HSV-1 Symptoms
HSV-1 is most commonly known for causing cold sores—small, fluid-filled blisters that usually appear around the lips or mouth. These cold sores may start with a tingling, itching, or burning sensation, followed by the appearance of blisters that eventually crust over and heal within a couple of weeks.
These outbreaks can be uncomfortable, but they usually follow a predictable path: a warning sensation, blister formation, and then healing. Common triggers for a recurrence include stress, illness, sun exposure, or a weakened immune system. The virus stays dormant in the body and tends to reactivate in the same area each time.
When HSV-1 affects the genitals, which is becoming more common due to oral-genital contact, the symptoms can look similar to those caused by HSV-2. However, genital HSV-1 infections usually recur less often and tend to be milder. People with genital HSV-1 may only have one outbreak, or none at all after the first one.
Antiviral medications like acyclovir can help manage symptoms and reduce how often outbreaks occur, whether HSV-1 is oral or genital.
One important note: Because HSV-1 has traditionally been associated with the mouth, genital infections caused by HSV-1 are sometimes missed or misdiagnosed. This is why proper testing—like PCR or type-specific blood tests—is key to getting the right information and care.
HSV-2 Symptoms
HSV-2 is the most common cause of genital herpes. It often starts with painful sores or ulcers in the genital or anal area, but it can also affect nearby areas like the buttocks or inner thighs. These sores may be accompanied by itching, tingling, or a burning feeling before they appear.
In women, HSV-2 may also cause vaginal discharge, cervicitis, or urethritis, and in men, it can cause urethral lesions. A first outbreak usually lasts 2–3 weeks, although it can take longer if left untreated.
HSV-2 tends to come back more often than HSV-1, especially in the genital area. Some people experience several outbreaks each year, and even when symptoms aren’t visible, the virus can still be present on the skin—this is called asymptomatic shedding. This makes HSV-2 easier to pass on, even without active sores.
Thankfully, daily antiviral medication can lower the frequency of outbreaks and reduce the risk of passing the virus to others. Still, it doesn’t fully eliminate the chance of shedding or reactivation.
The first outbreak of HSV-2 is often the most intense, and it can come with flu-like symptoms like fever, swollen lymph nodes, body aches, and fatigue. Some people may experience more severe complications, such as difficulty urinating or nerve-related pain. These cases are less common, but they do highlight why early diagnosis and supportive care matter.
Recurrence Patterns and Triggers
One of the key ways the difference between HSV-1 and HSV-2 shows up is in how often they come back. Both viruses can lie dormant in the body after the first infection, hiding out in nerve cells and reactivating later. But HSV-2 tends to recur more often, especially when it causes genital infections.
HSV-2 Recurs More Frequently
People with genital HSV-2 typically experience more outbreaks than those with genital HSV-1. On average, genital HSV-2 flares up several times a year—about one outbreak every three to four weeks. In contrast, genital HSV-1 is much less active, with some people having only one noticeable outbreak or none at all after the first episode.
More than 90% of people with HSV-2 and symptoms will have at least one recurrence in the first year. Over time, some may notice their outbreaks becoming less frequent or milder, but others continue to have recurring episodes long-term. Everyone’s experience is a little different, and the immune system plays a big role in how often the virus comes back.
Shared and Unique Triggers
Certain things can reactivate both HSV-1 and HSV-2, including:
- Emotional stress or physical exhaustion
- Fevers or other illnesses
- Immune system changes
- Skin trauma or injury
Sun exposure, especially UV light, is a well-known trigger for HSV-1, particularly in cases that affect the lips or eyes. Many people find that cold sores show up more in spring and summer when they’re spending more time outside.
For HSV-2, hormonal changes—like those during menstruation—are a common trigger, especially in women. Systemic inflammation, other infections, and immune suppression (like in people living with HIV) can also increase reactivation.
Recognizing these triggers can help people manage their health better and reduce how often outbreaks happen.
Where the Virus Hides and Why That Matters
Both HSV-1 and HSV-2 become dormant in the nervous system after the initial infection. HSV-1 usually settles in the trigeminal ganglia, which is linked to the face, while HSV-2 hides in the sacral ganglia, which affects the genital and lower body areas.
This is why symptoms tend to show up in the same places each time—the virus travels along the same nerve pathways during reactivation. HSV-2 also has a greater tendency to reactivate from multiple nerve centers at once, which may explain why its symptoms are often more persistent or widespread than HSV-1.
In people who carry both viruses at the same site, HSV-2 typically dominates, meaning it’s more likely to cause noticeable symptoms and recurrences.
Risk Factors and Long-Term Health Implications
One of the most important reasons to understand the difference between HSV-1 and HSV-2 is how HSV-2 affects long-term health—particularly its connection to HIV.
Research has consistently shown that people with HSV-2 are more likely to acquire HIV if exposed. In fact, having HSV-2 can double or even triple the risk of getting HIV, especially if the herpes infection is recent. In some high-prevalence areas, up to half of all new HIV cases may be linked to HSV-2.
Why is the risk so much higher? It comes down to how the body reacts to HSV-2. The virus often causes genital ulcers or tiny breaks in the skin, which create easy access points for HIV. HSV-2 also brings more HIV-targeting cells—like certain types of CD4+ T cells—to the surface of the skin and mucous membranes. These are the very cells HIV looks for to enter the body.
Even deeper in the immune system, HSV-2 can make things more complicated. It prompts the release of immune signals and peptides that increase the expression of HIV receptors on immune cells—essentially making it easier for HIV to gain a foothold.
What Happens When Both Viruses Are Present
When someone has both HSV-2 and HIV, each virus affects the other. HSV-2 reactivations become more frequent and severe, sometimes leading to long-lasting sores that are difficult to heal—these can be serious enough to be considered AIDS-defining illnesses.
At the same time, HIV levels tend to rise in the blood and genital tract when HSV-2 is active, making it easier to pass HIV to a sexual partner. Suppressive therapy for HSV-2, like daily antiviral medication, has been shown to lower HIV levels in the blood. However, in large studies, it hasn’t significantly reduced the chances of passing HIV on.
HSV-2 also complicates immune response. In people living with HIV, the immune cells that would normally keep HSV-2 in check don’t work as well. This means outbreaks can happen more often and be harder to manage.
A Bigger Public Health Picture
Beyond individual risk, HSV-2 plays a role in larger patterns of health inequity. In some communities, HSV-2 helps explain why certain groups—especially women and people of color—have higher rates of HIV. When researchers adjust for HSV-2, some of the gaps in HIV prevalence shrink, showing how deeply the two infections are intertwined.
This makes prevention and education even more critical. Knowing your HSV-2 status, practicing safer sex, and having access to testing and treatment can all make a real difference—not just for managing herpes, but for reducing HIV risk, too.
Neonatal Transmission Risks
Another important reason to understand the difference between HSV-1 and HSV-2 is their impact on newborn health. While both types can be passed from parent to baby, HSV-2 poses a higher risk during childbirth, particularly in first-time infections close to delivery.
HSV-2 Carries Greater Risk During Birth
When someone acquires genital HSV-2 late in pregnancy, the risk of passing it to their baby during delivery is highest. That’s because their body hasn’t had time to develop antibodies—immune defenses that normally help protect the baby during birth. In these cases, the chance of neonatal transmission can be as high as 50%.
In contrast, if a person already has HSV-2 and experiences a recurrence during labor, the risk of passing it on drops to about 1–3%. That’s thanks to the presence of existing antibodies, which help lower the likelihood of transmission.
Delivery method matters, too. If someone has active sores or is shedding the virus during labor, a cesarean section can drastically reduce the baby’s risk of infection. In fact, studies have shown that C-sections in these cases can lower transmission rates from nearly 8% to just over 1%. For this reason, current medical guidelines recommend cesarean delivery if there are signs of an active HSV infection at the time of birth.
When HSV-2 is passed to a newborn, it can cause serious health problems. The infection may spread throughout the body (disseminated herpes) or affect the central nervous system, leading to long-term brain and developmental issues—or even death in severe cases.
HSV-1 and Babies: Less Common, Still Serious
HSV-1 is less often linked to neonatal herpes, but that doesn’t mean it’s risk-free. As genital HSV-1 becomes more common in younger adults, more babies are being exposed during vaginal delivery. Additionally, HSV-1 can be transmitted after birth, especially if caregivers with active cold sores kiss or come into close contact with the baby.
Even though neonatal HSV-1 is generally less severe than HSV-2, it can still cause central nervous system infections or widespread illness. The good news is that the long-term neurological effects of HSV-1 tend to be milder than those seen with HSV-2.
Ultimately, prevention is rooted in awareness and care—knowing one’s HSV status during pregnancy, avoiding contact with cold sores when caring for infants, and working with healthcare providers to decide the safest delivery plan can go a long way in protecting newborns from infection.
Social and Psychological Considerations
The emotional side of a herpes diagnosis is just as real as the physical symptoms—sometimes even more so. While both HSV-1 and HSV-2 can bring challenges, the way they’re seen by society is often very different, and that difference can affect how people feel about themselves, their relationships, and their future.
The Stigma Divide
HSV-1 is generally more accepted, in part because it’s so common and usually picked up in childhood through non-sexual contact. Most people associate it with cold sores—something familiar and often shrugged off as a minor annoyance. This normalization makes it easier for people to talk about and live with HSV-1 without feeling judged.
HSV-2, on the other hand, carries a heavier emotional weight. Because it’s almost always linked to sexual contact, it’s often misunderstood and unfairly associated with negative stereotypes around sexual behavior. This stigma can lead to shame, embarrassment, or fear of being judged—emotions that can make it harder for someone to get tested, seek treatment, or talk openly with a partner.
Impact on Mental Health and Relationships
For many people, receiving an HSV diagnosis—especially HSV-2—can be emotionally overwhelming. Feelings of anxiety, sadness, or even grief are common. Worries about transmitting the virus, being rejected, or feeling “less than” in relationships can weigh heavily on someone’s mental health.
Unfortunately, the stigma around HSV isn’t just personal—it’s also shaped by how healthcare providers, media, and social circles talk about (or avoid talking about) the virus. When communication is lacking or laced with judgment, it can deepen feelings of isolation or confusion.
Romantic relationships can also be affected. People may delay or avoid disclosing their HSV status out of fear, which can strain connection and intimacy. Even in long-term relationships, fears about transmission and vulnerability may create distance.
But it’s important to remember: many people with HSV-1 or HSV-2 go on to have fulfilling, connected, and healthy relationships.
Supportive Communication Tips
Talking about HSV doesn’t have to be scary—it just takes honesty, care, and the right timing. Here are some ways to make the conversation a little easier:
If you’re sharing an HSV-1 diagnosis (oral or genital):
- Normalize it. You can point out how common HSV-1 is and that most people contract it through non-sexual means, often in childhood.
- If needed, explain the difference between oral and genital HSV-1, and reassure your partner that it’s manageable and typically causes mild symptoms.
If you’re sharing an HSV-2 diagnosis:
- Start from a place of confidence: HSV-2 is a common, manageable virus. It doesn’t define your worth or values.
- Choose a private, calm moment to talk. Focus on facts, like how many people have HSV-2, how treatment works, and how taking precautions can greatly lower the risk of passing it on.
- Encourage your partner to ask questions and be part of the conversation. You might even suggest reading up on it together if they’re unsure or nervous.
Above all, remember this: having HSV-1 or HSV-2 doesn’t make you unlovable, irresponsible, or alone. You deserve support, understanding, and relationships rooted in respect and openness.
Testing and Diagnosis Specifics
Getting an accurate diagnosis is one of the most empowering steps someone can take after potential exposure to herpes simplex virus. But not all tests are created equal—and understanding which type of HSV is present (HSV-1 or HSV-2) can make a big difference in treatment, communication, and long-term health planning.
How Testing Differentiates HSV-1 and HSV-2
There are several ways to test for HSV, but the most reliable methods are designed to tell the two virus types apart.
- Type-Specific Serology (TSS) is a blood test that checks for antibodies to HSV-1 and HSV-2 using specialized markers. These tests look for immune responses to specific proteins—called glycoprotein G (gG-1 for HSV-1 and gG-2 for HSV-2)—which helps ensure accurate typing. They’re especially helpful for detecting past exposure in people without symptoms or with a history of unclear outbreaks.
- PCR (Polymerase Chain Reaction) testing has become the gold standard for active infections. It’s done by swabbing a sore and looking for HSV’s genetic material. PCR tests are highly sensitive and can determine not just if HSV is present, but which type—often within hours. Modern platforms like the cobas® HSV test allow for fast, high-volume testing in clinical settings.
- Viral culture and antigen detection were once more common, but they’re now used less often. These methods can still identify HSV from a lesion but are less accurate—especially for HSV-1 or later-stage sores—and are being phased out in favor of PCR.
Why Type-Specific Testing Matters
Knowing the difference between HSV-1 and HSV-2 isn’t just academic—it guides care in real and practical ways.
- Clearer diagnosis: Many symptoms of HSV are non-specific or mild, and some people never have symptoms at all. Type-specific tests help prevent misdiagnosis or confusion, especially when genital sores are caused by HSV-1 or when no sores are visible.
- Essential for high-risk groups: Type-specific testing is strongly recommended for pregnant people, people living with HIV, and couples where one partner has HSV and the other does not. In these situations, knowing the exact type can shape important medical and relationship decisions.
- Better care and counseling: HSV-2 tends to cause more frequent genital outbreaks and is more likely to be spread through sexual contact, so people with HSV-2 may benefit from long-term suppressive therapy. Genital HSV-1, in contrast, usually causes fewer recurrences, and care can focus more on recognizing and managing occasional symptoms.
- More accurate risk discussions: Understanding which type is involved helps healthcare providers give better guidance on things like how the virus is transmitted (oral vs. genital), how to reduce the risk of passing it on, and what to consider during pregnancy or delivery.
- Avoiding unnecessary interventions: Misinterpreting a flare-up as a new infection—or the other way around—can lead to confusion and over-treatment, like recommending a cesarean birth when it’s not needed. Accurate testing can prevent these missteps and support better health outcomes.
Management and Treatment Considerations
Whether it’s HSV-1 or HSV-2, a herpes diagnosis doesn’t mean you’re out of options. There are effective treatments that can reduce symptoms, lower transmission risk, and improve quality of life. While the treatment tools are largely the same for both virus types, how they’re used often depends on the location of the infection, how often symptoms appear, and the needs of the person managing it.
Antiviral Therapies for Both Types
The mainstays of treatment—acyclovir, valacyclovir, and famciclovir—are used for both HSV-1 and HSV-2. These medications can shorten the length and severity of outbreaks and reduce how often the virus is shed, even when no symptoms are present. They work similarly across both types of HSV, but how they’re prescribed may differ.
- HSV-1 infections, especially those that affect the mouth, are often managed with episodic therapy—meaning medication is taken at the first sign of a flare-up.
- In more severe cases, like ocular HSV-1 or HSV that affects the nervous system, longer or ongoing treatment may be needed.
- HSV-2, particularly when it causes recurring genital outbreaks, may be managed with daily suppressive therapy or as-needed episodic treatment, depending on how often symptoms occur and the individual’s lifestyle.
Suppressive Therapy and HSV-2
Long-term suppressive therapy is more commonly recommended for HSV-2, especially for people who have frequent outbreaks or are in relationships where one partner does not have the virus. Daily antiviral medication can:
- Reduce symptoms by 70–80%
- Lower asymptomatic shedding by about 85%
- Significantly decrease the chance of transmitting HSV-2 to a partner
For people living with HIV, suppressive treatment of HSV-2 offers even more benefits. It helps lower the risk of HSV reactivation and co-transmission and may even slow HIV disease progression.
Suppressive therapy is especially helpful for people who:
- Have six or more outbreaks per year
- Experience significant emotional or social stress from the virus
- Want to reduce the chance of passing HSV to a partner
Lifestyle Management and Emotional Support
Alongside medication, lifestyle choices play a big role in managing both HSV-1 and HSV-2.
- Common triggers like stress, illness, poor sleep, and sun exposure (especially with HSV-1) can bring on outbreaks. Learning to identify and manage personal triggers is key to preventing flares.
- Practicing safer sex, avoiding skin-to-skin contact during outbreaks, and maintaining good hygiene can also reduce risk and support healing.
Support isn’t just about physical health—it’s emotional, too. Living with herpes, especially HSV-2, can carry psychological weight due to stigma or fear. That’s why many people benefit from:
- Honest conversations with healthcare providers
- Access to education and counseling
- Support groups or wellness programs that integrate emotional support with treatment plans
Finally, research into new treatments is ongoing. For severe or resistant cases, particularly in HSV-1-related eye disease, scientists are exploring newer therapies like immune-modulating treatments and targeted RNA-based approaches.
The bottom line? Both HSV-1 and HSV-2 are manageable. With the right tools, support, and information, people can lead full, connected, and healthy lives.
Understanding Your Diagnosis, Owning Your Health
Herpes simplex virus—whether it’s HSV-1 or HSV-2—is far more common than most people realize. And while the two types share many similarities, the difference between HSV-1 and HSV-2 matters: it shapes how symptoms appear, how the virus is passed on, and what kinds of support and treatment may be most helpful.
Throughout this article, we’ve explored how HSV-1 is often acquired in childhood and traditionally linked to oral cold sores, while HSV-2 is more closely tied to genital infections and tends to recur more frequently. We’ve also talked about how each virus spreads, how symptoms show up differently, and why getting a type-specific diagnosis is a key step in managing your health and protecting others.
We also looked at the emotional side of HSV, including the impact of stigma, the challenges of disclosure, and the strength it takes to move forward with honesty and self-compassion. Whether you’re newly diagnosed or supporting someone who is, it’s important to remember: you are not alone, and this does not define you.
With the right information, medical support, and communication tools, HSV is manageable. Your diagnosis can be a gateway to better self-awareness, deeper connections, and informed choices that put your health and wellbeing first.
If you found this article helpful and want to stay updated on future posts, resources, and tools for navigating HSV and other sexual health topics, sign up for our mailing list. We’re here to support you with science-based insights, empowering stories, and ongoing education—because everyone deserves access to care, clarity, and community.
References
Adelson, M., Feola, M., Trama, J., Tilton, R., & Mordechai, E. (2005). Simultaneous detection of herpes simplex virus types 1 and 2 by real-time PCR and Pyrosequencing. Journal of Clinical Virology, 33(1), 25-34.
Ahmed, W. A. M., Alghamdi, A. A., Almuhanna, R., Alazwari, A. A., Muddassir, R., & Elshony, H. S. (2023). Herpes Simplex Encephalitis with Normal Brain MRI and Normocellular Initial CSF. The International Journal of Neuroscience.
Al-Assaf, N., Moore, H., Leifso, K., Ben Fadel, N., & Ferretti, E. (2017). Disseminated neonatal herpes simplex virus type 1 after a water birth. Journal of the Pediatric Infectious Diseases Society, 6, e169-e172.
Antony, F., Kinha, D., Nowińska, A., Rouse, B. T., & Suryawanshi, A. (2024). The immunobiology of corneal HSV-1 infection and herpetic stromal keratitis. Clinical Microbiology Reviews.
Ayoub, H., Chemaitelly, H., & Abu-Raddad, L. (2019). Characterizing the transitioning epidemiology of herpes simplex virus type 1 in the USA. BMC Medicine, 17.
Bartlett, J. (2004). Recent developments in the management of herpes simplex virus infection in HIV-infected persons. Clinical Infectious Diseases, 39(Suppl 5), S237-S239.
Benedetti, J., Corey, L., & Ashley, R. (1994). Recurrence Rates in Genital Herpes after Symptomatic First-Episode Infection. Annals of Internal Medicine, 121, 847-854.
Benedetti, J., Zeh, J., & Corey, L. (1999). Clinical Reactivation of Genital Herpes Simplex Virus Infection Decreases in Frequency over Time. Annals of Internal Medicine, 131(1), 14-20.
Bobrow, M. (2016). Full Disclosure: Herpes Stigma and Communication Practices among HSV+ Individuals.
Bollen, A. E., Venema, A. W., & Veldkamp, K. E. (2007). Meningoradiculitis caused by herpes simplex virus type 2. Nederlands Tijdschrift voor Geneeskunde, 151, 2400-2404.
Brown, Z. (2002). Case study: type-specific HSV serology and the correct diagnosis of first-episode genital herpes during pregnancy. Herpes, 9(1), 24-26.
Brown, Z. A., Benedetti, J., Ashley, R., Burchett, S., Selke, S., Berry, S., Vontver, L., & Corey, L. (1991). Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. New England Journal of Medicine, 324(18), 1247-1252.
Brown, Z., Wald, A., Morrow, R., Selke, S., Zeh, J., & Corey, L. (2003). Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. JAMA, 289(2), 203-209.
Caulfield, P., & Willis, D. (2015). To disclose or not to disclose: The role of clinicians in advising patients about HSV disclosure. Sexually Transmitted Infections, 91, A34.
Celum, C. (2010). Sexually transmitted infections and HIV: Epidemiology and interventions. Topics in HIV Medicine, 18(4), 138-142.
Chayavichitsilp, P., Buckwalter, J. V., Krakowski, A., & Friedlander, S. (2009). Herpes simplex. Pediatrics in Review, 30(4), 119-129.
Cherpes, T. L., Matthews, D. B., & Maryak, S. A. (2012). Neonatal herpes simplex virus infection. Clinical Obstetrics and Gynecology, 55(4), 938-944.
Cuyugan, M. G., Mulugeta, W., Thabolingam-Haridas, M., Wilson, T., Augenbraun, M., Elsassy, T., & Cerniglia, B. (2011). Knowledge of HSV-2 Serostatus in Asymptomatic Adults. Sexually Transmitted Infections, 87, A243.
Daniels, D., & Mortlock, S. (2008). Mixed HSV-1 and HSV-2 infection in a patient attending a GUM clinic. British Journal of Biomedical Science, 65, 203-204.
Des Jarlais, D. D., Arasteh, K., McKnight, C., Perlman, D., Cooper, H., & Hagan, H. (2013). HSV-2 infection as a cause of female/male and racial/ethnic disparities in HIV infection. PLoS ONE, 8.
Diamond, C., Selke, S., Ashley, R., Benedetti, J., & Corey, L. (1999). Clinical course of patients with serologic evidence of recurrent genital herpes presenting with signs and symptoms of first episode disease. Sexually Transmitted Diseases, 26(4), 221-225.
Docherty, J. J., Trimble, J. J., Roman, S., Faulkner, S. C., Naugle, F. P., Mundon, F. K., & Zimmerman, D. H. (1985). Lack of oral HSV-2 in a college student population. Journal of Medical Virology, 16.
Edwards, S., & Carne, C. (1998). Oral sex and the transmission of viral STIs. Sexually Transmitted Infections, 74(1), 6-10.
Freedman, E., & Mindel, A. (2004). Epidemiology of herpes and HIV co-infection. Journal of HIV Therapy, 9(1), 4-8.
Guimarães, R., Rodovalho, A. G., Fernandes, I., Lucchese, R., & Vera, I. (2015). Inconsistent use of condoms in non-injecting illicit drug users. The Brazilian Journal of Infectious Diseases, 20, 220–221.
Gray, S. (2018). Clinical education extra: Cold sores. The Australian Pharmacist, 37, 62.
Hatchette, T. (2007). Herpes simplex virus type-specific serology: Where does it fit in the diagnostic armamentarium? Canadian Journal of Infectious Diseases & Medical Microbiology, 18(4), 225-227.
James, S. H., & Kimberlin, D. W. (2015). Neonatal herpes simplex virus infection: epidemiology and treatment. Clinics in Perinatology, 42(1), 47-59.
Johnston, C., Morrow, R., & Stanberry, L. (2014). Human Herpesviruses: Herpes Simplex Virus Types 1 and 2. In Human Herpesviruses (pp. 829-853).
Kumamoto, Y., Hirose, T., Ikegaki, S., Inoke, T., Gouro, T., Tabata, S., Yoshio, H., & Sakaoka, H. (1988). A clinical study of genital herpes and the clinical efficacy of acyclovir tablets. Hinyokika Kiyo, 34(2), 383-393.
Lafferty, W., Coombs, R., Benedetti, J., Critchlow, C., & Corey, L. (1987). Recurrences after oral and genital herpes simplex virus infection: Influence of site of infection and viral type. The New England Journal of Medicine, 316(23), 1444-1449.
Laycock, K., Lee, S. F., Brady, R., & Pepose, J. (1991). Characterization of a murine model of recurrent herpes simplex viral keratitis induced by ultraviolet B radiation. Investigative Ophthalmology & Visual Science, 32(10), 2741-2746.
Lee, S., Ives, A., & Bertke, A. (2015). Herpes Simplex Virus 1 Reactivates from Autonomic Ciliary Ganglia Independently from Sensory Trigeminal Ganglia To Cause Recurrent Ocular Disease. Journal of Virology, 89, 8383-8391.
Leruez-Ville, M., Driessen, M., Pichon, C., Sellier, Y., & Charlier, C. (2020). Herpes simplex virus infections during pregnancy: epidemiology, clinical presentation and management. Virologie, 24(5), 315-324.
Looker, K., Elmes, J., Gottlieb, S., Schiffer, J., Vickerman, P., Turner, K., & Boily, M. (2017). The effect of HSV-2 infection on subsequent HIV acquisition: An updated systematic review and meta-analysis. Sexually Transmitted Infections, 93, A137-A138.
Malkin, J. (2002). Natural history of HSV1 and HSV2 transmission and implications for HIV. Annales de Dermatologie et de Venereologie, 129(4 Pt 2), 571-576.
Marshall, G. (1997). Epidemiology and clinical manifestations of herpesvirus infections in infants and children. Seminars in Pediatric Infectious Diseases, 8(3), 151-168.
Martinelli, E., Tharinger, H., Frank, I., Arthos, J., Piatak, M., Lifson, J., … & Robbiani, M. (2011). HSV-2 infection of dendritic cells amplifies a highly susceptible HIV-1 cell target. PLoS Pathogens, 7.
Matak, M., & Matak, L. (2022). Unusual case presentation of genital herpes. Acta Dermatovenerologica Croatica, 30(3), 199-200.
McMicken, B., Kunihiro, A., & Wang, L. (2014). HSV-1 cold sores and genital involvement. Journal of Communication Disorders, Deaf Studies & Hearing Aids.
Mujugira, A., Magaret, A., Celum, C., et al. (2013). Daily acyclovir to decrease HSV-2 transmission from HSV-2/HIV-1 coinfected persons. Journal of Infectious Diseases, 208(9), 1366-1374.
Nakkawita, W., Mananwatta, S., & Galagoda, G. (2024). Seroprevalence of herpes simplex virus 2 infection among commercial sex workers in Colombo, Sri Lanka. Sri Lanka Journal of Medical Sciences.
Ndow, G., Manga, N., Bâ, I., Kà , D., Cisse-Diallo, V., Diop, S., … & Seydi, M. (2014). HSV Prevalence Among HIV Patients in South Africa. International Journal of Infectious Diseases, 21, 148.
Ogawa, Y., Kawamura, T., Matsuzawa, T., Aoki, R., Gee, P., Yamashita, A., … & Shimada, S. (2013). Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells. Cell Host & Microbe, 13(1), 77-86.
Pero, M., & Espinós, J. J. (2016). Genital HSV-1 Autotransmission Case Report. Journal of Clinical Case Reports, 2016.
Pol, B. (2016). Type-specific detection of herpes simplex virus type 1 and type 2 using the cobas’ HSV test. Expert Review of Molecular Diagnostics, 16, 1145-1154. https://pubmed.ncbi.nlm.nih.gov/27687862/
Posavad, C., Koelle, D., Shaughnessy, M., & Corey, L. (1997). Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proceedings of the National Academy of Sciences, 94(19), 10289-10294.
Ratnam, S., Severini, A., Zahariadis, G., Petric, M., & Romanowski, B. (2007). The diagnosis of genital herpes – beyond culture. Canadian Journal of Infectious Diseases & Medical Microbiology, 18(4), 233-240.
Reynolds, S. (2009). Role of HSV-2 suppressive therapy for HIV prevention. Future Microbiology, 4(9), 1095-1097.
Sacks, S., Griffiths, P., Corey, L., Cohen, C., Cunningham, A., Dusheiko, G., … & Whitley, R. (2004). HSV-2 transmission. Antiviral Research, 63(Suppl 1), S27-35.
Shearer, L., Simmons, L., Mindel, A., Stanberry, L., & Rosenthal, S. (2011). Reducing the stigma of HSV through brief publicly-generated videos. Sexually Transmitted Infections, 87, A259.
Shimomura, Y. (2008). Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis. Nippon Ganka Gakkai Zasshi, 112(3), 247-264.
Shrivastava, S. R., Shrivastava, P. S., & Ramasamy, J. (2019). Rising trends of herpes simplex virus – 1: A global public health concern. Indian Journal of Sexually Transmitted Diseases and AIDS, 40(2), 77-78.
Silva, A. (2015). HSV prevalence and siRNA therapy in herpetic encephalitis.
Skelly, M. J., Burger, A., & Adekola, O. (2012). HSV-1 encephalitis: Current management and case review. Antiviral Chemistry & Chemotherapy, 23, 13-18.
Sköldenberg, B. (1997). Genital Herpes: Past, Present and Future. Antiviral Chemistry and Chemotherapy, 8, 43.
Song, B., Dwyer, D., & Mindel, A. (2004). HSV type-specific serology in sexual health clinics. Sexually Transmitted Infections, 80, 113-117.
Strick, L. B., & Wald, A. (2012). Diagnostics for herpes simplex virus. Molecular Diagnosis & Therapy, 10, 17-28.
Sucato, G., Wald, A., Wakabayashi, E., Vieira, J., & Corey, L. (1998). Evidence of latency and reactivation of both herpes simplex virus (HSV)-1 and HSV-2 in the genital region. The Journal of Infectious Diseases, 177(4), 1069-1072.
Swearingen, J. A., & Ailor, S. (2007). Herpes simplex virus: It’s more than a cold sore. Missouri Medicine, 104(2), 144-148.
Syrjänen, S. (2006). Oral viral infections that could be transmitted oro-genitally. Oral Diseases, 12(S2), 2.
Sánchez-Alemán, M., Uribe-Salas, F., Lazcano-Ponce, E., García-Cisneros, S., Eguiza-Fano, S., & Conde-Glez, C. (2010). HSV-2 seroincidence among Mexican college students. Sexually Transmitted Infections, 86, 565–569.
Taback, N., & Bradley, C. (2006). Validation of the Genital Herpes Treatment Satisfaction Questionnaire (GHerpTSQ). Quality of Life Research, 15, 1043-1052.
van Velthoven, M. H., Lam, C., de Cock, C., Stenfors, T., Chaudhury, H., & Meinert, E. (2020). Development of an Innovative Real-World Evidence Registry for HSV: Case Study. Journal of Medical Internet Research, 22.
Ventura, A., Merajver, S., Shew, M., Kahn, J., DeKruyff, R., & Umetsu, D. (2013). HSV Reactivation and Shedding.
Wald, A., & Ashley-Morrow, R. (2002). Serological testing for herpes simplex virus (HSV)-1 and HSV-2. Clinical Infectious Diseases, 35(Suppl 2), S173-S182.
Wald, A., Langenberg, A., Krantz, E., Douglas, J., Handsfield, H., DiCarlo, R., … & Corey, L. (2005). The relationship between condom use and herpes simplex virus acquisition. Annals of Internal Medicine, 143(10), 707-713.
Wald, A., Langenberg, A., Link, K., Izu, A., Ashley, R., Warren, T., … & Corey, L. (2001). Effect of condoms on reducing the transmission of herpes simplex virus type 2. JAMA, 285(24), 3100-3106.
Wald, A., Schacker, T., & Corey, L. (1997). HSV-2 and HIV: consequences of an endemic opportunistic infection. STEP Perspective, 9(3), 2-4.
Wen, P., Liao, Q., Li, W., Chen, M., Ma, C., & Han, J. (2013). Detection of Anti-HSV-2 Antibodies for Genital Herpes Diagnosis. Chinese Journal of Dermatology, 46, 771-774.
Whale, J., Clarke, E., Patel, N., Graham, C., Ingham, R., & Patel, R. (2013). Psychological experiment on stigma and HSV-1 disclosure. Sexually Transmitted Infections, 89, A39.
Wilkinson, D., & Barton, S. (2001). Use of type-specific HSV serology in the management of a 37-year-old woman. Herpes, 8(1), 4-7.
Wu, E., Sayre, J., Wiesmeier, E., Bernstein, D., Visscher, B., & Bryson, Y. (1984). HSV-1 and HSV-2 in College Population. Pediatric Research, 18, 289A.
Zuckerman, R., Lucchetti, A., Whittington, W., et al. (2009). HSV suppression reduces seminal HIV-1 levels in co-infected men. AIDS, 23, 479-483.
